市場調查報告書

Harvoni:醫藥品的考察與到2030年為止的預測

Harvoni- Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 968224
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Harvoni:醫藥品的考察與到2030年為止的預測 Harvoni- Drug Insight and Market Forecast - 2030
出版日期: 2020年10月31日內容資訊: 英文 50 Pages
簡介

Harvoni是C型肝炎病毒(HCV)NS5A抑制劑ledipasvir和HCV核苷酸類比NS5B聚合酵素抑制劑sofosbuvir的固定劑量複方藥物,使用治療成人和3歲以上的兒童患者的HCV治療。

本報告提供美國,德國,法國,義大利,西班牙,英國日本的主要7個國家,C型慢性肝炎病毒治療藥Harvoni調查,產品概要,SWOT分析,藥事法規方面的里程碑,市場評估,競爭產品,新的治療藥等資訊。

目錄

第1章 產品概要

  • 症狀
  • 作用機制
  • 投藥和管理
    • 劑型和有效性成分含量
  • 合成途徑
  • 藥理學
    • 藥效學
    • 藥物動力學
  • 副作用
  • 產品的概述
  • 開發里程碑
  • 市售詳細內容
    • 美國
    • 歐洲
    • 日本
  • 專利詳細內容

第2章 SWOT分析

  • 分析師的見解

第3章 藥事法規方面的里程碑

  • 核准
  • 研究開發
  • 臨床試驗資訊
  • 安全性和有效性
  • 產品開發活動

第4章 市場評估

  • 主要7個國家的市場分析
  • 美國
  • 歐洲
  • 日本
  • 主要調查結果

第5章 競爭產品

第6章 新治療方法

第7章 附錄

  • 報告的購買選擇
目錄
Product Code: DIDM0079

"Harvoni- Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Harvoni in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary:

Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older:

  • Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
  • Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin
  • Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Harvoni.
  • The report contains historical and forecasted sales for Harvoni till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Harvoni.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Harvoni Analytical Perspective by DelveInsight

  • In-depth Harvoni Market Assessment

This report provides a detailed market assessment of Harvoni in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Harvoni Clinical Assessment

The report provides the clinical trials information of Harvoni covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Harvoni is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Harvoni dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Harvoni and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Harvoni.
  • Our in-depth analysis of the sales data of Harvoni from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Harvoni in the market.

Key Questions:

  • What is the prescribed dosage and strengths of Harvoni are available in the market?
  • What are the common adverse reactions or side effects of Harvoni?
  • What is the product type, route of administration and mechanism of action of Harvoni?
  • What are the chemical specifications of Harvoni?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Harvoni, and what is its future?
  • What are the marketed details of Harvoni in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Harvoni and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Harvoni?
  • In which countries Harvoni got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Harvoni?
  • How the safety and efficacy results determined the approval of Harvoni?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Harvoni development?
  • What are the key designations that have been granted to Harvoni?
  • What is the historical and forecasted market scenario of Harvoni?
  • How is the market trend of Harvoni is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Harvoni?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Harvoni
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options

List of Tables

  • Table 1 Harvoni, Description
  • Table 2 Harvoni, Trial Diversification
  • Table 3 Harvoni, Marketed Details United States
  • Table 4 Harvoni, Marketed Details Europe
  • Table 5 Harvoni, Marketed Details Japan
  • Table 6 Patent Details: Harvoni
  • Table 7 Harvoni, Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Harvoni
  • Table 9 Harvoni, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Harvoni, US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Harvoni, EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Harvoni, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Harvoni, Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Harvoni
  • Figure 2 Patent Details, Harvoni
  • Figure 3 Harvoni, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Harvoni, US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Harvoni, EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Harvoni, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Harvoni, Japan Market Size from 2017 to 2030 (in Millions USD)